Intraday Nifty Future Tips : Cipla gains 1% on partnership with Roche Pharma
The company entered into an agreement with Roche Pharma under which Cipla will promote and distribute Tocilizumab (Actemra) and Syndyma, the 2nd brand of Roche’s cancer therapy, bevacizumab (Avastin) in India.
This partnership is in line with Cipla and Roche’s efforts to improve healthcare and increase access to innovative, life-changing medicines in India, particularly to patients who currently do not have access to them.
Umang Vohra, MD & Global CEO of Cipla said, “The prevalence of cancer and rheumatoid arthritis is widely spread across India, and Cipla can contribute to providing broader access to innovative medicines like tocilizumab and bevacizumab.
Two days Free Trials and best services packages for dealing in Stock market click here to get >>Nifty Future Trading Tips
We look forward to promoting and distributing the drugs in India in furtherance of our philosophy of Caring for Life.”